海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02637 海西新药

交易中 11-04 10:39:17

143.100

+0.700

+0.49%

最高144.500	最低141.000	成交量2,600
今开141.000	昨收142.400	日振幅2.46%
总市值112.63亿	流通市值112.63亿	总股本7,871万
成交额37.21万	换手率0.00%	流通股本7,871万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":143.1,"timestamp":1793759238364,"preClose":142.4,"halted":0,"volume":2600,"delay":0,"changeRate":0.004915730337078572,"floatShares":78707270,"shares":78707270,"eps":2.55,"marketStatus":"交易中","change":0.7,"latestTime":"11-04 10:39:17","open":141,"high":144.5,"low":141,"amount":372135,"amplitude":0.024579,"askPrice":143.2,"askSize":300,"bidPrice":142.5,"bidSize":150,"shortable":3,"etf":0,"ttmEps":2.305238,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1793764800000},"marketStatusCode":2,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":142.4,"openAndCloseTimeList":[[1793755800000,1793764800000],[1793768400000,1793779200000]],"volumeRatio":0.33047,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637/wiki","defaultTab":"wiki","newsList":[{"id":"1165183204","title":"海西新药10月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1165183204","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165183204?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:36","pubTimestamp":1793608619,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司（以下简称“海西新药”）于2026年11月2日发布的10月股份变动月报表显示，该公司于报告期内（截至2026年10月31日）注册股本及已发行股份总数均未发生变动。\n海西新药本月报披露，其法定/注册股本维持人民币78,707,270元不变；无新增或减少事项。截至当月末，普通股H股的已发行股份数量维持在78,707,270股，库藏股份数量为0股，总体股本保持稳定。公告亦确认本月没有新增股份发行、股份购回、注销或库藏股变动，也无涉及股份期权及股权激励计划的相关变动。\n公司方面指出，已满足香港联交所的最低公众持股量要求。公告由联席公司秘书张俊环签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677679464","title":"机构研报覆盖预示市场风向标，加速创新转型的海西新药(02637)估值修复可期？","url":"https://stock-news.laohu8.com/highlight/detail?id=2677679464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677679464?lang=zh_cn&edition=full","pubTime":"2026-10-21 20:21","pubTimestamp":1792585286,"startTime":"0","endTime":"0","summary":"在此背景下，海海西新药股价表现却稍显逊色。不过，海西新药在这段下行通道中的股价并非单边下跌，而是高波动下跌与反弹修复反复交替。多家机构研报覆盖，市场风向标显现8月18日之后，海西新药股价在高位分歧后整体趋势明显走弱，并在接下来2个月内逐渐到向缩量破位下行的空头技术结构中。公告披露后，国内多家机构更新了相关研报，整体上对海西新药的创新管线给予了较高预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["REVS","02637","NIFE","BK1191","LCO","CZA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121560201","title":"海西新药（02637）更新股份奖励计划进展：已购回39.49万股H股，占总股本0.502%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121560201","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121560201?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:35","pubTimestamp":1792485346,"startTime":"0","endTime":"0","summary":"海西新药（02637）10月20日发布自愿公告，披露股份奖励计划的最新进展。截至2026年10月16日，为实施该计划而委任的受托人已在香港联合交易所二级市场累计购入394,900股H股，约占公司截至本公告日期已发行股份总数的0.502%。\\n\\n公司表示，上述股份将以信托方式持有，并根据股份奖励计划条款用于后续授予。未来任何进一步的股份购买将视市场情况而定，时间、数量及价格均无法保证。\\n\\n海西新药提醒投资者在买卖公司股份时保持审慎，如有疑问应寻求专业意见。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676048651","title":"【券商聚焦】国泰海通维持海西新药（02637）增持 指口服眼底新药潜力凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2676048651","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676048651?lang=zh_cn&edition=full","pubTime":"2026-10-20 13:44","pubTimestamp":1792475093,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券发布研报指，海西新药 口服眼底病新药HX9428的I期与II期数据高度一致，疗效与安全性得到初步验证，口服大单品潜力凸显。维持2026-2028年归母净利润2.17、2.57、2.80亿元人民币预测。HX9428凭借眼球富集、全身快速清除的分子设计，有望解决注射剂依从性痛点，进军全球超百亿美元的抗VEGF市场。I期13例患者完成24周治疗，BCVA平均提升5.2个字母，CST下降73.3μm。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993958","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK0276","BK0012","BK1191","BK0183","KCE","601211","BK0201","BK0028","BK0188","02611","BK1147","BK0184","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675316385","title":"港股异动 | 海西新药(02637)盘中涨超5% HX9428将进入BD谈判合作加速全球3期开发的最佳窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2675316385","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675316385?lang=zh_cn&edition=full","pubTime":"2026-10-14 14:45","pubTimestamp":1791960333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药(02637)盘中涨超5%。截至发稿，涨4.29%，报160.5港元，成交额1073.53万港元。消息面上，海西新药于9月公告，HX9428用于治疗新生血管性年龄相关性黄斑变性(nAMD)的中国I期临床研究已完成24周治疗数据观察；中国II期剂量扩展研究目前仍在进行中，并已取得阶段性临床数据。华福证券指出，随着国内2b期的头对头阿柏西普数据读出，叠加美国2a期最佳剂量探索验证欧美人群初步疗效和安全性，HX9428将进入BD谈判合作，并通过合作伙伴加速全球3期开发的最佳窗口期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","VXUS","BK4588","KCAI","BK4585","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674782456","title":"【券商聚焦】华福证券维持海西新药（02637）买入评级 指HX9428临床数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2674782456","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674782456?lang=zh_cn&edition=full","pubTime":"2026-10-12 14:29","pubTimestamp":1791786595,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华福证券发布研报指，海西新药 自主研发的口服小分子创新药物HX9428正开展nAMD相关临床研究，I/II期临床已初步验证疗效优异且安全性良好。公司已在中国正式启动HX9428治疗nAMD的多中心、随机、开放、阳性对照II期临床研究，计划招募60例受试者，头对头对比阿柏西普。海外方面，美国II期临床试验申请已获FDA批准，HX9428并被FDA授予快速通道资格。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993440","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","161027","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674139835","title":"【券商聚焦】兴业证券首予海西新药（02637）增持评级 指HX9428临床成果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2674139835","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674139835?lang=zh_cn&edition=full","pubTime":"2026-10-09 14:11","pubTimestamp":1791526313,"startTime":"0","endTime":"0","summary":"HX9428治疗nAMD的I/II期临床取得积极阶段性成果。公司于2026年8月31日向CDE递交HX9428新适应症DME的IIa期IND；HX9428于8月17日获FDA快速通道资格，nAMD适应症IND于8月5日获FDA批准。国内随机对照II期nAMD研究已启动，计划招募60例受试者，头对头对比HX9428与阿柏西普的有效性及安全性。兴业证券认为，HX9428有望解决视网膜血管疾病眼内注射治疗依从性差、治疗率低的问题，后续需关注阳性对照临床数据表现及长期用药安全性。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993381","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","601377","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137007572","title":"海西新药9月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1137007572","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137007572?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:39","pubTimestamp":1791275944,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司于2026年10月6日发布截至2026年9月30日的证券变动月报表。报告显示，9月期间公司股本保持稳定，未发生新增发行、购回、注销或库藏股变动。同时，公司9月期间无涉及股份期权、权证或可转债相关的发行或变动，也未订立任何其他有待发行股份的协议或安排。本次月报表由联席公司秘书张俊环签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671680295","title":"招商证券：海西新药(02637.HK)HX9428有望填补口服治疗nAMD蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2671680295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671680295?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:44","pubTimestamp":1790660665,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1147","BK1564","02637","BK1191","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671295681","title":"招商证券：海西新药(02637)HX9428有望填补口服治疗nAMD蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2671295681","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671295681?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:44","pubTimestamp":1790660665,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，海西新药口服眼底病创新药HX9428有望解决临床治疗痛点，潜在市场空间广阔，首次覆盖给予\"增持\"评级。HX9428作为口服小分子眼底病创新药，无需眼内注射即可发挥治疗作用，可同时覆盖双眼病变，显著降低长期治疗负担，有望为眼底病慢病管理提供全新给药路径，填补口服治疗的空白市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1564","600999","BK1191","06099","02637","BK1147","BK0183","BK0010","BK0012","BK0028","BK0276","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176753997","title":"海西新药2026年中期营收3.12亿元，净利润81.05百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176753997","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176753997?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:13","pubTimestamp":1790244836,"startTime":"0","endTime":"0","summary":"根据公司公告，海西新药在2026年中期录得营收约3.12亿元，同比增长3.8%。同期净利润为81.05百万元，相比上一年同期的107.81百万元下降24.82%。成本结构方面，报告期内营业成本从上一年同期的40.62百万元增至56.46百万元，同比增长39.02%。研发投入则由27.12百万元增加至40.76百万元，同比提高50.32%，约占报告期营收的13.07%。公司在报告期内的经营活动现金流净额为80.56百万元，同比降低30.21%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"海西新药2026年中期营收3.12亿元，净利润81.05百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667834319","title":"海西新药(02637)：HX9428用于治疗nAMD的I期临床研究已完成24周治疗数据观察 II期剂量扩展研究取得阶段性临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2667834319","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667834319?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:26","pubTimestamp":1789561585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，HX9428用于治疗新生血管性年龄相关性黄斑变性的中国I期临床研究已完成24周治疗数据观察;中国II期剂量扩展研究目前仍在进行中，并已取得阶段性临床数据。HX9428中国I期临床研究共纳入15例nAMD患者，覆盖5 mg/QD至40 mg/QD五个剂量组。HX9428中国II期剂量扩展研究目前仍在进行中。公司将持续监测各项安全性指标，并进一步评估HX9428的长期获益风险特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海西新药(02637)：HX9428用于治疗nAMD的I期临床研究已完成24周治疗数据观察 II期剂量扩展研究取得阶段性临床数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181985415","title":"海西新药（02637）公布HX9428治疗nAMD I期及II期阶段性临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1181985415","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181985415?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:25","pubTimestamp":1789561531,"startTime":"0","endTime":"0","summary":"2026年9月16日，福建海西新药创制股份有限公司发布自愿公告，更新口服小分子候选药物HX9428用于新生血管性年龄相关性黄斑变性的中国I期及II期临床研究进展。截至2026年8月14日，5 mg/QD、10 mg/QD及20 mg/QD三组共入组80例患者，其中约78%为既往接受anti-VEGF治疗患者，约22%为初治患者；45例已完成第13周访视，11例已完成24周治疗。公告提示，HX9428尚未获得任何国家或地区药品监管机构批准上市，临床研究仍在进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617679","title":"创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617679","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617679?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:20","pubTimestamp":1789525259,"startTime":"0","endTime":"0","summary":"消息面上，国金证券表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。诚通证券表示，2025年为创新药海外授权BD大年，2026H1我国创新药海外授权BD交易继续大幅增长，总交易金额已接近1000亿美元，国产创新药已从偶发性出海转变为系统性趋势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991724","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0359201612.USD","LU0327786744.USD","09688","BK0060","LU0348825331.USD","LU0561508036.HKD","02637","06978","LU1255011170.USD","IE00BZ08YS42.EUR","01477","BK0188","LU0307460666.USD","LU1328615791.USD","LU0456846285.SGD","KURE","MEDX","LU1997244956.HKD","IBBQ","LU2148510915.USD","LU0516422952.EUR","02269","LU2097828805.USD","LU0417516902.SGD","BK1515","LU2039709279.SGD","BK0239","LU0140636845.USD","LU0043850808.USD","LU1580142542.USD","159992","LU0405327148.USD","LU2580892789.USD","LU0128526141.USD","LU2488822045.USD","LU1820825898.SGD","LU0348827113.USD","BK0183","LU2097828557.USD","LNGR","IE00B0JY6N72.USD","LU1023057109.AUD","LU0516423174.USD","01276","01177","LU1655091616.SGD","LU0588546209.SGD","600276","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667148376","title":"港股异动 | 海西新药(02637)涨超3% 近期已递交HX9428的DME IIa期新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2667148376","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667148376?lang=zh_cn&edition=full","pubTime":"2026-09-15 14:48","pubTimestamp":1789454932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超3%，截至发稿，涨2.89%，报195.5港元，成交额618.26万港元。消息面上，海西新药发布公告，本公司自主研发的创新药项目HXP056的候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。公司表示，将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","KCAI","IBBJ","MDTX","VXUS","BK1191","BK4588","BK4585","BMED","PSYK","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530067","title":"【券商聚焦】国投证券首予海西新药（02637）“买入-A”评级 指口服眼药潜力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530067","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666530067?lang=zh_cn&edition=full","pubTime":"2026-09-09 14:15","pubTimestamp":1788934513,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，海西新药 核心产品口服VEGFR2小分子HXP056存在颠覆眼底病治疗标准的潜力，有望凭口服优势抢占当前注射眼药市场份额。采用DCF法估值，假设10.0%折现率、2.0%永续增长率，得到公司价值约192.7亿元人民币，对应目标价266.80港元，首次给予买入-A评级。风险提示包括HXP056安全性不及预期、临床开发进度及结果不及预期、产品销售放量不及预期及计算假设不及预期风险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991157","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","161027","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新药：已提交自研创新药HX9428临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819950?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日，海西新药（02637）发布公告，公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","IBBJ","06978","159992","BK1574","IBBQ","MEDX","MDTX","BK1191","02637","BK1161","PSYK","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134622913","title":"海西新药（02637）口服眼底药HX9428完成nAMD一期临床并向NMPA递交DME二期IND","url":"https://stock-news.laohu8.com/highlight/detail?id=1134622913","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134622913?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:22","pubTimestamp":1788348136,"startTime":"0","endTime":"0","summary":"2026年9月2日，海西新药公布，其自主研发的候选药物HX9428已于2026年8月31日向中国国家药品监督管理局药品审评中心递交糖尿病性黄斑水肿IIa期临床试验申请。该适应症为HX9428推进的第二个开发方向。HX9428为口服小分子药物，拟用于nAMD、DME及视网膜静脉阻塞等血管性视网膜疾病。截至公告日期，HX9428尚未获得任何监管机构上市批准，其安全性与有效性仍需进一步临床验证。公司提醒投资者，创新药研发存在高风险，HX9428能否最终获批上市尚存在不确定性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681635","title":"海西新药(02637)：HX9428顺利完成新生血管性年龄相关性黄斑变性(nAMD)之I期临床研究并递交新适应症糖尿病性黄斑水肿(DME)之IIa 期新药临床试验申请(IND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681635","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681635?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:18","pubTimestamp":1788347924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，本公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局 药品审评中心递交新适应症糖尿病性黄斑水肿的 IIa期新药临床试验申请。上述初步数据显示HX9428具有良好的安全性特征及潜在疗效信号，其安全性及有效性尚需透过进一步临床研究予以验证。本公司将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","02637","IND","IBBQ","IBBJ","BK1191","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105163555","title":"海西新药8月股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1105163555","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105163555?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:11","pubTimestamp":1788343906,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司于2026年9月2日发布2026年8月31日止月份的证券变动月报表。公告显示，公司于8月无新增发行、购回或注销股份活动，股本保持稳定。公司表示，其8月末已符合适用的香港联交所规定的最低公众持股量要求。综上所述，截至8月末，公司股本维持不变。本次公告由联席公司秘书张俊环代表公司签署，体现公司遵守香港联交所《上市规则》及相关法规的合规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":0.0142},{"period":"1month","weight":-0.1264},{"period":"3month","weight":-0.2873},{"period":"6month","weight":-0.438},{"period":"1year","weight":0.1788},{"period":"ytd","weight":0.0471}],"compareEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0922},{"period":"6month","weight":-0.1164},{"period":"1year","weight":-0.1006},{"period":"ytd","weight":-0.0821}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"福建海西新药创制股份有限公司成立于2012年3月27日。公司是一家处于商业化阶段的制药公司,集研发、生产及销售能力于一体,具备在研创新药的管线。公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期,公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药。根据灼识咨询的资料,该等治疗领域占2023年中国医药销售总额的25%以上。公司的创新药管线专注于具有各种适应症的在研药物,包括一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性(wAMD)╱糖尿病性黄斑水肿(DME)╱视网膜静脉阻塞(RVO)的首款口服药物及另外两款处于临床前阶段,用于治疗肿瘤及呼吸系统疾病的创新在研药物。公司所有在研创新药均由内部以专有方式开发及发展。","exchange":"SEHK","name":"海西新药","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海西新药,02637,海西新药股票,海西新药股票老虎,海西新药股票老虎国际,海西新药行情,海西新药股票行情,海西新药股价,海西新药股市,海西新药股票价格,海西新药股票交易,海西新药股票购买,海西新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}